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Adeno-associated virus (AAV) delivery of potent and broadly
neutralizing antibodies (bNAbs is a promising approach for
the prevention of HIV-1 infection. The immunoglobulin
G (IgG)1 subtype is usually selected for this application,
because it efﬁciently mediates antibody effector functions
and has a somewhat longer half-life. However, the use of
IgG1-Fc has been associated with the generation of anti-
drug antibodies (ADAs) that correlate with loss of antibody
expression. In contrast, we have shown that expression of
the antibody-like molecule eCD4-Ig bearing a rhesus IgG2-
Fc domain showed reduced immunogenicity and completely
protected rhesus macaques from simian-HIV (SHIV)-AD8
challenges. To directly compare the performance of the
IgG1-Fc and the IgG2-Fc domains in a prophylactic setting,
we compared AAV1 expression of rhesus IgG1 and IgG2
forms of four anti-HIV bNAbs: 3BNC117, NIH45-46, 10-
1074, and PGT121. Interestingly, IgG2-isotyped bNAbs eli-
cited signiﬁcantly lower ADA than their IgG1 counterparts.
We also observed signiﬁcant protection from two SHIV-
AD8 challenges in macaques expressing IgG2-isotyped
bNAbs, but not from those expressing IgG1. Our data suggest
that monoclonal antibodies isotyped with IgG2-Fc domains
are less immunogenic than their IgG1 counterparts, and
they highlight ADAs as a key barrier to the use of AAV1-ex-
pressed bNAbs.
INTRODUCTION
To date, no HIV-1 vaccine approaches have elicited potent broadly
neutralizing antibodies (bNAbs) in humans, but bNAbs emerge natu-
rally in some HIV-1-positive individuals after several years of
infection (reviewed in Burton and Mascola1). These bNAbs target
multiple epitopes of the HIV-1 envelope glycoprotein (Env),
including the CD4-binding site, the N332 V3-glycan site, the V1V2
apex, the gp120/gp41 interface, and the membrane-proximal external
region (MPER). Passive infusion of bNAbs can protect rhesus ma-
caques from infection with simian-HIVs (SHIVs),2 and it can be
used to suppress an established SHIV infection.3,4 Currently, three
bNAbs have been evaluated in clinical trials for safety and therapeutic
efﬁcacy.5–9 Two of these, 3BNC117 and VRC01, target the CD4-bind-
ing site, and one, 10-1074, targets sequences that include the N332
glycan at the base of the V3 loop.
One way to bypass the need to develop bNAbs through vaccina-
tion is through the use of adeno-associated virus (AAV) vectors.
These vectors have been used to express bNAbs and other bio-
logics to prevent HIV-1 or SHIV transmission in animal models.
Prophylaxis studies pioneered by Johnson et al.10 showed that
AAV-delivered immunoadhesins could protect most rhesus ma-
caques from an SIVmac316 challenge. Balazs et al.11,12 extended
this approach by showing that AAV8-delivered bNAbs could pro-
tect humanized mice from HIV-1. However, more recent macaque
studies made it clear that AAV1- and AAV8-delivered bNAbs are
frequently targeted by host immune responses, limiting their
expression and efﬁcacy.13–15 To develop an effective AAV-based
HIV-1 vaccine alternative, it will, therefore, be necessary to mini-
mize immune system-mediated clearance of the AAV-expressed
transgene.
The most effective human HIV-1 vaccine trial to date identiﬁed non-
neutralizing antibodies recognizing the HIV-1 Env variable domains
1 and 2 as a correlate of protection,16,17 although this interpretation
has been contested.18 These observations, combined with studies in
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animal models, raise the possibility that antibody effector functions
might play an important role in preventing HIV-1 transmission.19,20
Thus, antibodies with immunoglobulin G (IgG)1 Fc domains are
generally used to study antibody-mediated prophylaxis. In every study
of AAV1-delivered bNAbs in rhesus macaques, rhesus IgG1-Fc do-
mains were used, high anti-drug antibody (ADA) responses were
observed, and these ADAs limited or abrogated protection.13–15
Conversely, AAV1-delivered rh-eCD4-Ig that included a rhesus
IgG2-Fc domain afforded robust protection from SHIV-AD8 chal-
lenges.21 We thus hypothesized that AAV-delivered bNAbs and
eCD4-Ig with IgG2-Fc domains would afford greater protection than
their IgG1 counterparts, because the IgG2-Fc may elicit fewer ADAs
that limit serum concentrations or activity of the AAV-expressed
transgene.
Here we show that macaques inoculated with recombinant AAV1
vectors expressing rhesusized bNAbs with IgG1-Fc domains had
high ADAs; low bNAb titers; and, in general, were poorly pro-
tected from SHIV-AD8 challenges. However, bNAb combinations
with rhesus IgG2-Fc domains elicited fewer ADAs than their
IgG1 counterparts, and, partly as a consequence, we observed sig-
niﬁcant SHIV-AD8 protection in macaques expressing bNAbs with
Figure 1. Functional Characterization of HIV-1
bNAbs Expressed from an AAV Gene Cassette
(A) A diagram of the gene cassette used to express bNAbs
from an AAV vector. ITR, inverted terminal repeat; CMVp,
cytomegalovirus promoter; VH, heavy-chain variable
domain; rh-CH, rhesus macaque heavy-chain constant
domain; VL, light-chain variable domain; rh-CL, rhesus
macaque light-chain constant domain; WPRE, wood-
chuck hepatitis virus post-transcriptional regulatory
element; pA, SV40 polyadenylation signal sequence. (B)
SHIV-AD8 neutralization studies of human IgG1 bNAbs
(black) and their rhesus IgG1 (red) and IgG2 (blue) coun-
terparts purified from supernatants of 293T cells trans-
fected with transfer plasmids represented in (A). Error bars
indicate SEM.
IgG2-Fc domains. Our data suggest that IgG2
forms of bNAbs and other biologics may be
useful to limit ADAs in contexts where anti-
body effector functions are unnecessary or
less relevant.
RESULTS
Expression of AAV1-Delivered bNAbs
Stabilizes at Low Concentrations
To test the role of isotype in prophylaxis, the
variable regions of four bNAbs—PGT121,
10-1074, 3BCN117, and NIH45-46—were com-
bined with rhesus-derived IgG1 or IgG2 con-
stant regions. 3BNC117 and NIH45-46 are
CD4-binding site antibodies derived from the
same heavy-chain germline-variable gene allele
(VH1-2), but from distinct donors. PGT121 and 10-1074 are
N332-glycan antibodies from the same donor.22 Rhesus IgG1 and
IgG2 forms of the heavy chains of these antibodies were cloned
into a previously described vector alongside rhesus forms of their
respective light chains,23 as depicted in Figure 1A. The framework re-
gions of bNAb-variable regions were not rhesusized, because these
mutations are necessary for bNAb potency.24 The rhesusized bNAbs
expressed from these transfer plasmids neutralized SHIV-AD8 with
similar efﬁciencies, regardless of species-origin or Fc-domain isotype
(Figure 1B). The most notable difference was 3BNC117 with a rhesus
IgG2-Fc showed to be roughly 5-fold less potent than the human
IgG1 3BNC117.
Recombinant AAV1 vectors encoding the rhesusized IgG1 or IgG2
versions of the four bNAbs were then evaluated for expression
in NSG (NOD/SCID/IL2Rg/) mice. Eight groups of four mice
per group were with 1011 total genome copies (GCs) of the
AAV1 vectors encoding one of the eight bNAbs (Figure 2A).
Concentrations at 4 weeks post-inoculation ranged from 80–
143 mg/mL 3BNC117, 33–158 mg/mL 10-1074, 15–58 mg/mL
NIH45-46, and 6–47 mg/mL PGT121. In three of four cases,
no differences were observed in expression and total average
www.moleculartherapy.org
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expression was nearly identical (Figure 2B). However, there was a
notable difference in PGT121 IgG2 expression compared to the
IgG1 version.
To determine if bNAb expression patterns were similar in mice
and macaques, a group of 12 rhesus macaques were inoculated
with 1013 GCs of a recombinant AAV1 vector encoding either
IgG1 or IgG2 forms of one CD4-binding site antibody
(3BNC117 or NIH45-46) and the same amount of a vector encod-
ing an N332-glycan antibody (10-1074 or PGT121) of the same
isotype. Note that CD4-binding site antibodies used kappa light
chains, whereas N332-glycan antibodies used lambda light chains.
This feature allowed measurement of both bNAbs in the same an-
imal by using secondary antibodies that reacted with only the
kappa or lambda light chain of the bNAb. We observed that
bNAb titers peaked at 2–4 weeks, ranging from 3 to 69 mg/mL,
and then rapidly declined, in most cases to <1 mg/mL by week 8
(Figures 3A and 3B). Notably, IgG2 bNAbs had signiﬁcantly
greater peak expression than their IgG1 counterparts (Figure 3C;
p value of 0.04), but these differences diminished over time (Fig-
ure 3D). However, the signiﬁcance of these peak expression differ-
ences disappeared if PGT121 was excluded from this analysis
(p value of 0.06). In addition to a trend toward higher expression
associated with IgG2, 10-1074 appeared to reach higher levels
in vivo than did the other antibodies.
Figure 2. bNAbExpression fromAAV1Vectors in NSG
Mice
(A) Concentrations of rhesusized IgG1 (red) or IgG2 (blue)
bNAbs in NSGmice. Mice were inoculated with 1011 AAV1
vectors encoding the indicated bNAb in the gastrocnemius
muscle. Plasma samples were taken from weekly blood
draws for 4 weeks, and bNAb concentrations were
determined by gp120 ELISA. Error bars indicate the range
of measured values. (B) Comparison of bNAb titers from
mice expressing IgG1 or IgG2 bNAbs at 4 weeks post-
AAV1 inoculation. *n.s., not significant based on unpaired
t test.
Emergence of ADA Coincides with a
Decrease in bNAb Expression
Given their low expression, we investigated
whether the rapid decline in bNAb titers was
associated with the emergence of ADA. ADA
was observed in all 12 macaques and against all
bNAbs (Figures 4A and 4B). In general, 10-
1074 appeared to be less immunogenic than the
other antibodies. Notably, in several other cases,
ADAs declined to below background levels over
the 20-week study, but they remained high in
others. Because ADA measurements at week 4
reached the upper limits of the ELISA used and
remained high throughout the course of the
study, serial dilutions at this time point were per-
formed using the week 4 and week 20 time point
samples (Figures 5A and 5B). These dilutions made clear that, over
the course of the study, ADAs against IgG1-isotyped bNAbs were
signiﬁcantly greater than those elicited by IgG2 bNAbs (Figures 5C
and 5D). Thus, the higher concentrations of IgG2 bNAbs observed
in the ﬁrst several weeks following AAV1 inoculation correlated
with lower ADAs in this time frame.
ADA Responses Target the Variable Regions of AAV-Delivered
HIV-1 bNAbs
Measured ADAs remained largely consistent whether IgG1 or IgG2
isotypes of each individual bNAb were used to coat the ELISA plate
(Figures S1A and S1B), indicating that most ADAs targeted the
bNAb-variable regions. We also investigated whether ADA against
one bNAb of a class would cross-react with another bNAb from the
same class (Figures S2A and S2B). We observed cross-reactivity be-
tween the CD4-binding site antibodies 3BNC117 and NIH45-46,
which originate from a common variable heavy-chain gene, in four
of 12 cases. ADA appeared to be antibody speciﬁc, with the exception
of some cross-reactivity found in closely related bNAbs. We also
observed cross-reactivity between N332-glycan antibodies 10-1074
and PGT121 in seven of 12 cases. These antibodies arose from the
same VDJ recombination event. Altogether, our data indicate that
most ADAs targeted the bNAb-variable regions and ADA cross-reac-
tivity between related antibodies argues against the use of similar
bNAbs in antibody cocktails.
Molecular Therapy
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Macaques Expressing IgG2-Isotyped, but Not IgG1-Isotyped,
bNAbs Are Partially Protected from Low-Dose SHIV-AD8
Challenges
The 12 bNAb-expressing macaques, along with four control animals,
were then challenged intravenously with SHIV-AD8.25 Animals
received a 100 pg p27 dose at week 8 post-AAV1 inoculation and a
200 pg dose at week 10 post-AAV1 inoculation (Figure 6A). The chal-
lenge doses selected were based on our previous study where a 200-pg
p27 dose of this same SHIV-AD8 stock infected 50% of control ani-
mals.21 After the ﬁrst challenge, none of the animals expressing IgG2
bNAbs were infected. In contrast, 67% of animals expressing IgG1
bNAbs and 50% of the control animals became infected. After the sec-
ond challenge, 50% of macaques with IgG2 bNAbs, 83% of macaques
with IgG1 bNAbs, and all the control macaques were infected. Signif-
Figure 3. Concentrations of AAV-Delivered HIV-1
bNAbs with Rhesus IgG1 or IgG2 Constant Regions
(A and B) Concentrations of rhesusized IgG1 (A, red) and
IgG2 (B, blue) bNAbs in rhesus macaques inoculated
intramuscularly with 1013 AAV GCs of each indicated
antibody. Dots to the right of animal identification number
indicate protection from SHIV-AD8, as described in Fig-
ure 6. (C and D) Comparison of bNAb titers from ma-
caques expressing IgG1 or IgG2 bNAbs at the peak of
expression (C) or the post-peak average (weeks 6–20
post-AAV inoculation) (D). Open circles indicate animals
protected from two SHIV-AD8 challenges. Dotted lines
indicate limit of detection of the ELISA. Error bars in (A)
and (B) indicate range of measured values. Bars in (C) and
(D) indicate mean and SD.
icant protection was observed with IgG2 bNAbs
(p = 0.032, Mantel-Cox test), whereas macaques
expressing IgG1 bNAbs did not show signiﬁ-
cant protection relative to the control animals
(p = 0.915, Mantel-Cox test). No difference in
viral loads post-infection were observed in any
group (Figure 6B). Differences among antibody
pairs were also not signiﬁcant (Figures S3A–
S3C). Protection correlated with lower ADAs
against the expressed antibodies at week 4
post-inoculation (Figure 7A) and higher
average post-peak expression (weeks 6–20
post-AAV1 inoculation) of an N332-glycan
antibody (Figure 7B), but it was independent
of CD4-binding site antibody expression (Fig-
ure 7C). Thus, lower ADAs and higher bNAb
concentrations, associated with AAV-delivered
IgG2-bearing bNAbs, correlated with greater
protection.
DISCUSSION
All HIV-1 vaccine candidates have so far failed
to elicit bNAbs thought necessary for sterilizing
protection of the global population. Passively
administered bNAbs can effectively prevent HIV-1 transmission,
but this approach requires repeated injections for at-risk groups
over prolonged periods. In contrast, AAV vectors have the potential
to provide ameans of durably expressing protective titers of bNAbs or
engineered proteins like eCD4-Ig.21 A key challenge to developing
AAV-based vaccine approaches is the problem of ADAs. This prob-
lem may have been exacerbated by the human origin of the antibody
variable region and by the extensive somatic hypermutation of these
bNAbs. Although ADAs have been associated with passively infused
antibodies or biologics in humans (reviewed in Krishna and Na-
dler26), they appear less pronounced when a bNAb is passively
infused than when it is delivered via AAV.27 This is likely because
the viral vector includes a capsid that is foreign to the host and the
viral DNA is likely to stimulate innate immune responses (reviewed
www.moleculartherapy.org
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previously28–30). Inﬂammation at the site of injection may further
exacerbate these responses. Thus, muscle-injected AAV, and espe-
cially AAV1, appears to function as a potent adjuvant,31 increasing
the likelihood of ADAs and of cell-mediated clearance of transduced
cells.32
Macaque studies of AAV1-expressed bNAbs, modiﬁed with rhesus
macaque constant regions, have shown that ADA is indeed a key
concern in this context.13–15 In contrast, we have previously shown
that ADAs to rhesus eCD4-Ig were modest and did not impede
prophylaxis.21 Two factors may contribute to this difference.
First, eCD4-Ig includes fewer non-self elements than the heavily
hypermutated bNAb-variable regions. Second, eCD4-Ig bears a
rhesus IgG2-Fc domain, whereas, to date, every primate study of
bNAbs utilized rhesus IgG1. Our data here suggest that both
factors contribute. Speciﬁcally, every bNAb combination tested
here elicited ADAs to some extent, regardless of isotype. Of
note, 10-1074 appeared to be less immunogenic than the other
three bNAbs, even less immunogenic than 3BNC117 expressed
in the same animals, consistent with its greater similarity to germ-
line antibody sequences.13 However, IgG2 bNAbs afforded signif-
icant protection compared with controls, although this protection
was much less robust than in our previous study with eCD4-
IgG2.21
The basis for the greater immunogenicity and clearance of IgG1-
isotyped proteins remains to be deﬁned. We speculate that antigen-
presenting cells more efﬁciently internalize IgG1 through their Fc
receptors, ultimately promoted by ADA production and cytotoxic
lymphocyte (CTL)-mediated clearance of transgene-expressing cells.
ADAs can also frequently abrogate the activity of passively adminis-
tered antibodies and biologics used to treat a range of conditions.33,34
Our data suggest that IgG2 may also help limit these ADAs as well.
The residual immunogenicity of AAV1-delivered bNAbs remains a
challenge, especially if administered to a diverse human population.
The AAV1 serotype for the vectors used in this study has been shown
to be an especially immunogenic AAV serotype, and fewer ADAs
have been observed with AAV8, for example.35 However, high
ADAs have been observed with the AAV8-delivered simianized
bNAb VRC07, with a rhesus IgG1-Fc domain.14 Alternatively, target-
ing the liver for expression of the transgene may also help by inducing
tolerance to the transgene itself.36–38 Ongoing efforts to regulate
transgene expression may help to delay expression until after the
initial innate response to the vector capsid and DNA abates.39 It
may also be beneﬁcial to explore the use of Toll-like receptor (TLR)
9 antagonists40,41 and programmed cell death protein 1 (PD-1) ago-
nists42 as a means of limiting immune responses at the site of inocu-
lation and rapamycin to induce T regulatory cells.43–45
Figure 4. Host ADA Responses against AAV-Expressed IgG1 or IgG2 Versions of HIV-1 bNAbs
(A and B) ADA monitored over the course of 20 weeks in macaques expressing the indicated IgG1 (A, red) or IgG2 (B, blue) bNAbs, as determined by ELISA. Sera samples
used for the analysis at the indicated time points were diluted 20-fold. Values indicate absorbance at 450 nM. Error bars indicate range of measured values. Dotted lines
indicate the average absorbance value of AAV-negative control samples before and after SHIV-AD8 infection. Dots to the right of animal identification numbers indicate
protection from SHIV-AD8, as described in Figure 5.
Molecular Therapy
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AAV-expressed anti-HIV inhibitors can serve as an effective vaccine
alternative. Unlike current conventional HIV-1 vaccines, this
approach requires a one-time inoculation that provides durable pro-
tection. The challenge of ADAs will nonetheless be an obstacle that
needs to be addressed. In addition, all AAV-delivered antibody
approaches require further study of their safety and perhaps including
a means of halting transgene expression. Our data shown here indi-
cate that AAV-delivered bNAbs can prevent HIV-1 infection if these
challenges are met.
MATERIALS AND METHODS
Non-human Primates, Inoculations, and Challenges
The 16 animals described in this study were Indian-origin rhesus
macaques (Macaca mulatta), all between 2 and 5 years of age at the
time of AAV1 inoculations. All macaques were housed at the New
England Primate Research Center in accordance with standards set
forth by the American Association for Accreditation of Laboratory
Animal Care. This study was performed with the approval of the
appropriate Institutional Animal Care and Use Committee (IACUC).
All macaques were AAV1 and SIV negative at the beginning of the
study. All macaques were negative for Mamu B*08 and B*17 alleles.
Macaques that were positive for the Mamu A*01 or A*02 alleles
were divided evenly among groups when possible. Macaque ages
ranged from 1.92 to 2.25 years old at the time of AAV inoculation.
Macaques were inoculated in a quadriceps muscle with 1 mL saline
containing 1013 AAV1 GCs encoding one CD4-binding site antibody
and, in the other quadriceps, 1 mL saline containing 1013 AAV1 GCs
encoding oneN332-glycan antibody. Eachquadriceps received two in-
jections of 0.5 mL each. Thus, three macaques received vectors
encoding IgG1 forms of 3BNC117 and 10-1074, three macaques
received IgG2 forms of these same antibodies, threemacaques received
IgG1 forms of NIH45-46 and PGT121, and three macaques received
Figure 5. ADA Responses in Macaques Expressing IgG1 and IgG2 bNAbs at 4 and 20 Weeks Post-AAV1 Inoculation
(A–D) Assays similar to those of Figure 3 are shown, except that week 4 and 20 sera samples were serially diluted. Red indicates that sera from macaques expressing the
indicated IgG1 bNAbs were analyzed (A), whereas blue indicates that macaques expressing IgG2 bNAbs were analyzed. Dots to the right of animal identification indicate
protection fromSHIV-AD8, as described in Figure 5. Error bars indicate range of measured values. (E) The reciprocal serum dilution that yields levels of ADA at an A450 = 0.3 as
determined in (A) and (B) is compared. (F) The reciprocal serum dilution that yields levels of ADA at an A450 = 0.3 as determined in (C) and (D) is compared. Bars indicate mean
and SD. *p < 0.05, based on unpaired t test.
www.moleculartherapy.org
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IgG2 forms of these antibodies. 1 mL sera was obtained every
1–2 weeks post-AAV inoculation. Animals were initially challenged
with 100 pg p27 SHIV-AD8-EO intravenously. Uninfected animals
were re-challenged intravenously 2 weeks later with 200 pg p27
SHIV-AD8-EO intravenously. Plasma viral loads were quantiﬁed by
RT-PCR as previously described.3
Cell Lines and Plasmids
HEK293T cells were obtained from ATCC and grown in DMEMwith
10% fetal bovine serum at 37C. TZM-bl cells were obtained through
the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH
fromDr. John C. Kappes, Dr. XiaoyunWu, and Tranzyme and grown
in DMEM with 10% fetal bovine serum at 37C.46–50 The plasmids
encoding SHIV-AD8-EO have been previously described.21 Rhesus
macaque IgG1 and IgG2 sequences were based on those described
by Scinicariello et al.51 The rhesus IgG2 isotype versions of
3BNC117, NIH45-46, 10-1074, and PGT121 and the rhesus IgG1 iso-
type versions of 3BNC117 and 10-1074 have been previously
described.13,21 The rhesus NIH45-46-IgG1 and rhesus PGT121-
IgG1 plasmids were generated by cloning a codon-optimized gene
(Genewiz, South Plainﬁeld, NJ) into an AAV transfer plasmid con-
taining AAV2 inverted terminal repeats (ITRs) using the NotI-clon-
ing sites. The plasmids encoding the human versions of the heavy and
light chains of 3BNC117, NIH45-46, and 10-1074 were previously
described.52 Human PGT121 heavy- and light-chain expression plas-
mids were a generous gift from Dennis Burton.
Protein Production and Purification
Production of antibodies was performed as previously described.52
Brieﬂy, HEK293T cells in 175-mm plates were transfected with
Figure 6. Isotype-Dependent Protection in
Macaques Expressing bNAb Pairs
(A) Kaplan-Meier curves indicating infection of control
macaques (gray) or macaques expressing IgG1 bNAb
pairs (red) or IgG2 bNAb pairs (blue), with intravenous
challenge doses at weeks 8 and 10 post AAV-inoculation
indicated on the horizontal axis. As shown at the right,
significant protection was observed only with IgG2-ex-
pressing macaques (Mantel-Cox test). (B) Viral loads of
macaques expressing IgG1 (red) or IgG2 (blue) bNAbs
aligned at the time of infection. The left panel depicts
macaques expressing 3BNC117 and 10-1074. The right
panel depicts macaques expressing NIH45-46 and
PGT121. Dotted gray lines show viral loads of control
macaques. No significant differences in viral loads were
observed between any groups. Dots to the right of animal
identification indicate protection from SHIV-AD8 after two
challenges.
80 mg total DNA/plate at 50% conﬂuency with
a calcium phosphate transfection kit (Takara,
Mountain View, CA). For human antibody pro-
duction, cells were co-transfected with both
heavy-chain vector and light-chain vector at a
1:1 ratio. For rhesus antibody production, cells were co-transfected
with AAV transfer plasmid and a plasmid encoding furin at a 4:1
ratio. At 12–16 hr post-transfection, 10% fetal bovine serum (FBS)-
DMEM was replaced with serum-free 293 Freestyle media (Invitro-
gen, Carlsbad, CA). Media were collected after 48 h, and debris
was cleared by centrifugation for 10 min at 1,500  g and ﬁltered
using 0.45-mm ﬁlter ﬂasks (Millipore Sigma, Billerica, MA). Proteins
were isolated with HiTrap columns (GE Healthcare, Pittsburgh, PA)
and eluted with IgG Elution Buffer (Thermo Scientiﬁc, Waltham,
MA) into 1 M Tris-HCl Buffer (pH 9.0) (G Biosciences, St. Louis,
MO). Buffer was exchanged with PBS and protein concentrated to
1 mg/mL with Amicon Ultra Centrifugation Filters (Millipore Sigma,
Billerica, MA). Antibodies were stored at 4C.
TZM-bl Neutralization Assay
TZM-bl neutralization assays were performed as previously
described.53 Brieﬂy, SHIV-AD8 was pre-incubated with titrated
amounts of antibody in DMEM (10% FBS) for 1 h at 37C. TZM-
bl cells were detached by trypsinization, diluted in DMEM (10%
FBS) to 100,000 cells/mL, and added to the virus and inhibitor
mixture. Cells were then incubated for 44 h at 37C. Viral entry
was analyzed using Britelite Plus (PerkinElmer, Waltham, MA),
and luciferase was measured using a Victor X3 plate reader (Perki-
nElmer, Waltham, MA).
AAV1 Production and Purification
Production of recombinant AAV1, at the University of Massachusetts
Medical School Vector Core, has been previously described.54 In
short, HEK293T cells were transfected with an AAV vector plasmid,
a plasmid encoding AAV2 rep and AAV1 cap, and a helper plasmid
Molecular Therapy
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encoding adenovirus genes. After harvesting lysates of transfected
cells, AAV was puriﬁed through three sequential cesium chloride
(CsCl) centrifugation steps. The vector genome copy number was as-
sessed by RT-PCR. The integrity of AAV particles was veriﬁed by
electron microscopy (EM), and the purity of the AAV preparations
was veriﬁed by silver-stained SDS-PAGE.
AAV1 Expression of bNAbs in Mice
32 male NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ mice (NSG/Nod scid
gamma) were obtained from The Jackson Laboratory. Mice were
inoculated with 1011 total genome copies of recombinant AAV1 vec-
tors encoding one of the IgG1 or IgG2 versions of 3BNC117, 10-1074,
NIH45-46, or PGT121 at a 25-mL volume in the left gastrocnemius
muscle. Mice were bled weekly for 4 weeks, and plasma samples
were obtained by centrifuging blood samples at 11,000  g for
3 min. Plasma was frozen on dry ice and kept at 80C until used
for analysis by gp120 ELISA.
Challenge Virus Production
293T cells were plated in 175-mm ﬂasks and transfected with 80 mg
SHIV-AD8-EO by calcium phosphate technique. At 12 h post-trans-
fection, medium was replaced with fresh DMEM (10% FBS). Medium
was harvested at 48 h post-transfection, and debris was cleared by
centrifugation for 10min at 1,500 g and ﬁltered using 0.45-mm ﬁlter
ﬂasks (Millipore Sigma, Billerica, MA). Virus stocks were aliquoted
and frozen at 80C. Virus titers were determined by an SIV p27
ELISA kit (ABL, Rockville, MD).
gp120 and ADA ELISAs
Half-area 96-well Costar Assay Plates (Corning) were coated with
5 mg/mL gp120 (Immune Tech, New York, NY). Plates were washed
with PBS-T (PBS + 0.05% Tween-20) twice and blocked with 5%milk
in PBS for 1 h at 37C. Sera samples were serially diluted in 5%milk in
PBS and were added to the plate in duplicate. Standard curves were
generated by diluting 4 mg/mL standard protein in 5%milk, then seri-
ally diluted and added to the plate in duplicate. Plates were incubated
for 1 h at 37C. Samples were washed ﬁve times with PBS-T, and a
horseradish peroxidase secondary antibody was added. To determine
3BNC117 andNIH45-46 levels, a secondary antibody recognizing hu-
man kappa light chain was used (Southern Biotech, Birmingham,
AL). To determine 10-1074 and PGT121 levels, a secondary antibody
recognizing human lambda light chain was used (Southern Biotech).
Plates were incubated for 1 h at 37C and then washed ten times with
PBS-T. 3,3’,5,5’-Tetramethylbenzidine (TMB) solution (Fisher) was
added, and plates were incubated at room temperature until their
standard curves developed (typically 5–10 min). TMB Stop Solution
(Southern Biotech, Birmingham, AL) was then added and absorbance
was read at 450 nm by a Victor X3 plate reader (PerkinElmer, Wal-
tham, MA). Standard curves were analyzed using GraphPad Prism
6.0 software and used to determine protein titers from sera samples.
Sera samples frommacaques expressing bNAbs were analyzed against
the macaque IgG1 and IgG2 versions of 3BNC117, NIH45-46, 10-
1074, and PGT121. Sera samples were diluted 20-fold and blocked
in 5% milk in PBS. ADAs from macaques expressing bNAbs were
measured using secondary antibodies detecting either kappa or
lambda light chains (Southern Biotech, Birmingham, AL) opposite
to the antibody being assayed. Plates were incubated for 1 h at
37C. TMB solution was added for 10 min at room temperature.
Stop solution was then added and absorbance at 450 nm was
measured as described above.
Ethics Statement
These studies were performed at the New England Primate Research
Center, and the statements below apply throughout the time frame of
these studies. The animal management program of Harvard Medical
School is accredited by the American Association for the Accredita-
tion of Laboratory Animal Care, and it meets NIH standards as set
forth in the Guide for the Care and Use of Laboratory Animals
(DHHS Publication No. [NIH]85-23 Revised 1985, “The NIH
Guide”). The Institute also accepts as mandatory the PHS Policy on
Humane Care and Use of Laboratory Animals by Awardee Institu-
tions and NIH Principles for the Utilization and Care of Vertebrate
Animals Used in Testing, Research, and Training. There is on ﬁle
Figure 7. Correlates of SHIV-AD8 Protection by Macaques Expressing AAV-Delivered bNAbs
(A) Comparison of the reciprocal serum dilution that yields background levels of ADA as determined in Figure 3 for macaques that were protected and unprotected fromSHIV-
AD8 challenges. Red indicates IgG1 and blue indicates IgG2. Circles indicate 3BNC117 or NIH45-46 and squares indicate 10-1074 or PGT121. (B and C) Comparison of
bNAb concentrations for N332-glycan bNAbs (B) or CD4-binding site bNAbs (C) for protected and unprotected macaques from SHIV-AD8 challenges. Concentration values
are derived from the time point before the macaque became infected or week 10 if protected. Red indicates IgG1 and blue indicates IgG2. Circles indicate 10-1074 (B) or
3BNC117 (C); squares indicate PGT121 (B) or NIH45-46 (C). Bars indicate mean with SD. *p < 0.05 and **p < 0.01 based on unpaired t test; n.s., not significant.
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with the Ofﬁce for Protection from Research Risks an approved
Assurance of Compliance.
Animal facilities met Harvard standards for humane care and use
of animals through a program of veterinary care, inspection, and
oversight. Animal care and welfare were the charge of the Committee
on Animals, appointed by the Dean, consisting of 22 members
comprising 4 veterinarians, 2 public representatives, and 16
doctoral-level representatives of principal sites of animal use by
Harvard Faculty. Additionally, local facilities were guided and moni-
tored in daily activities by 8 departmental animal use committees.
The procedures to avoid unnecessary discomfort, pain, or injury to
animals are those prescribed in the aforementioned NIH Guide, and
additional detailed protocols for anesthesia, analgesia, tranquilization,
euthanasia, or restraint have been developed and circulated by the
Committee on Animals.
Rhesus macaques on study were housed in the biocontainment facil-
ity of the New England Primate Research Center of Harvard Medical
School under approved protocol 04888 of the IACUC of Harvard
Medical School. Animals housed in the biocontainment facilities
received a daily health check by both animal care technicians and
veterinary professional staff. All animals received a complete physical
examination on the average of once every 4–6 weeks. A comprehen-
sive environmental enrichment and psychological well-being
plan was in place for primates in the described studies, and it is
available for inspection by the United States Animal and Plant Health
Inspection Service (APHIS) and to ofﬁcials of any pertinent organi-
zation. Euthanasia took place at deﬁned experimental endpoints
using protocols consistent with the American Veterinary Medical
Association (AVMA) guidelines. Animals were ﬁrst sedated with
intramuscular ketamine hydrochloride at 20 mg/kg body followed
by sodium pentobarbital (R100 mg/kg) intravenously to achieve
euthanasia.
Statistical Analyses
All statistical analyses were performed using GraphPad Prism 6.07
software (GraphPad, La Jolla, CA). Comparisons of groups were per-
formed using Student’s t test or Mantel-Cox test as reported in the
ﬁgure legends. Statistical signiﬁcance is reported as a p value% 0.05.
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